Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDA
Women, older people and minorities are enrolled less frequently in lung cancer drug trials and the numbers do not reflect the prevalence of lung cancer in these populations, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC). "Our results suggest that the trial population used for approval of drugs do not represent well the U.S. population who may receive the marketed agent," said principal investigator Dr. Shakun Malik, a medical officer at the U.S. Food and Drug Administration (FDA) in Silver Spring, Maryland.
Researchers reviewed trial data submitted for FDA drug approvals for the treatment of non-small cell lung cancer (NSCLC) over the last decade.
Of U.S. patients diagnosed with lung cancer according to the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) data released on April 15, 2011, and collected between years 1975-2008, 58% were men and 42% women. But in 10 national and international trials for agents approved to treat NSCLC between January 2000 and December 2010, 68% of enrollees were men and 32% were women.
In addition, 73% of U.S. lung cancer patients are older than 65 but only 36% of the drug trial population was older than 65, researchers found.
Meanwhile, African-Americans develop lung cancer at higher rates (72.7 per 100,000) than Caucasians (68 per 100,000), but only 2% of trial participants were black. Caucasians made up 78% of the trial population, Asians 15%, Hispanics 2% and "other" 2%.
"Disparity was especially pronounced in the age and ethnicity," Dr. Malik wrote. "This fact is concerning particularly for older patients who may experience greater toxicity when given the same dose and combination of drugs based on testing in a younger population."
Source: International Association for the Study of Lung Cancer
Articles on the same topic
- TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to dateThu, 7 Jul 2011, 8:33:38 UTC
- Endosonography followed by surgical staging improves quality of life, according to ASTER studyThu, 7 Jul 2011, 8:33:26 UTC
- Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinuxThu, 7 Jul 2011, 8:33:16 UTC
- TGen presents lung cancer studies at Amsterdam conferenceThu, 7 Jul 2011, 7:33:39 UTC
- Canada's Cancer Risk Management model is an important new health tool for policymakersWed, 6 Jul 2011, 8:33:41 UTC
- Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009Wed, 6 Jul 2011, 8:33:06 UTC
- Increased investment in thoracic surgical expertise increased UK lung cancer resection rateWed, 6 Jul 2011, 8:32:53 UTC
- First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conferenceWed, 6 Jul 2011, 7:35:20 UTC
- Celecoxib may prevent lung cancer in former smokersWed, 6 Jul 2011, 4:33:12 UTC
- High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy Tue, 5 Jul 2011, 9:02:35 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation ConsortiumTue, 5 Jul 2011, 9:02:25 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersTue, 5 Jul 2011, 9:02:15 UTC
- EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapyTue, 5 Jul 2011, 9:02:06 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsTue, 5 Jul 2011, 9:01:57 UTC
Other sources
- Endosonography followed by surgical staging improves quality of life, according to new studyfrom Science DailyThu, 7 Jul 2011, 14:30:50 UTC
- TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to datefrom PhysorgThu, 7 Jul 2011, 11:00:24 UTC
- Endosonography followed by surgical staging improves quality of life, according to ASTER studyfrom PhysorgThu, 7 Jul 2011, 11:00:22 UTC
- Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinuxfrom PhysorgThu, 7 Jul 2011, 11:00:21 UTC
- TGen presents lung cancer studies at Amsterdam conferencefrom PhysorgThu, 7 Jul 2011, 8:01:37 UTC
- Celecoxib may prevent lung cancer in former smokersfrom Science DailyWed, 6 Jul 2011, 20:32:45 UTC
- Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDAfrom PhysorgWed, 6 Jul 2011, 14:30:50 UTC
- Canada's Cancer Risk Management model is an important new health tool for policymakersfrom PhysorgWed, 6 Jul 2011, 14:30:49 UTC
- Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009from PhysorgWed, 6 Jul 2011, 14:01:53 UTC
- Increased investment in thoracic surgical expertise increased UK lung cancer resection ratefrom PhysorgWed, 6 Jul 2011, 14:01:45 UTC
- Celecoxib may prevent lung cancer in former smokersfrom PhysorgWed, 6 Jul 2011, 7:30:43 UTC
- First whole-genome lung cancer study set for conferencefrom PhysorgWed, 6 Jul 2011, 7:30:31 UTC
- Drug may prevent lung cancer in former smokersfrom Science BlogWed, 6 Jul 2011, 4:30:47 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortiumfrom Science DailyTue, 5 Jul 2011, 14:31:06 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersfrom Science DailyTue, 5 Jul 2011, 14:31:05 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsfrom Science DailyTue, 5 Jul 2011, 14:31:04 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsfrom PhysorgTue, 5 Jul 2011, 9:00:23 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortiumfrom PhysorgTue, 5 Jul 2011, 9:00:22 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersfrom PhysorgTue, 5 Jul 2011, 9:00:22 UTC
- High EGFR expression a predictor for improved survival with cetuximab plus chemotherapyfrom PhysorgTue, 5 Jul 2011, 9:00:21 UTC
- EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapyfrom PhysorgTue, 5 Jul 2011, 9:00:20 UTC